CD274 and neoplasm: Neoadjuvant therapy can specifically bind to PD-1 or PD-L1 to block the PD-1/PD-L1 signaling pathway so that T cells can restore the immune response against tumors, thereby increasing the killing of tumor cells (35, 36).